GHKs strong antioxidant and anti-inflammatory activity and ability to control post-injury oxidative damage has led to strong research interest in its use to help subjects recover from tissue injury [1, 6]
The problem with this philosophy is that obesity is not a short-term condition
When they reach their goals, they do not want to stay reliant on the medication
By engaging two complementary pathways involved in appetite regulation and satiety, Amycretin is designed to offer superior weight loss outcomes

1 Total Randomized Trial Population Completer Population Upon discontinuation of treatment, patients are likely to regain weight 3-5 53% of Saxenda patients and 45% of patients on placebo completed the 3-year trial 3 The safety profile over 3 years was consistent with the profile at 1 year 3 Study 1 (3 years) 1,3 Results from a 160-week, randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of Saxenda Adult patients with pre-diabetes and with a BMI of either 30, or 27 with at least 1 additional comorbidity were randomized to receive once-daily Saxenda (n=1,505) or placebo (n=749) in conjunction with a lifestyle modification program that included increased physical activity and a 500-kcal/day-deficit diet Patients underwent a 4-week dose-escalation period followed by 156 weeks on the full dose, with a 12-week off-drug observational follow-up period The study evaluated percentage of patients achieving weight loss of at least 5% of body weight at both 1 and 3 years Mean baseline body weight was 236.7 lb and mean BMI was 38.8 kg/m 2 In patients with obesity, losing weight causes changes in appetite hormones that can actually increase hunger and the desire to eat

doi: 10.3389/fcvm.2021.723886 Received 11 June 2021 Accepted 14 October 2021 Published 23 November 2021 Volume 8 - 2021 Edited by Dianjianyi Sun, Peking University, China Reviewed by Nhat Tu Le, Houston Methodist Research Institute, United States